COVID-19 has changed the landscape of healthcare and has, over the past 2 years, dramatically revitalized investor interest in the sector. With Western and Chinese investors, the most knowledgeable that they have ever been in vaccine and pharmaceutical development processes, we have seen growing flows of investment capital into all aspects of healthcare.
While blue-chip companies like Pfizer, Johnson and Johnson, and even Moderna should be on every investor’s watchlist, the up-and-coming small-cap healthcare companies provide some of the most impressive growth opportunities. Finding the next major market mover means looking at the cutting edge of new treatments, technologies, and medical devices! The upcoming Healthcare Investment Conference will feature ideas from North America and China together for the audience to watch and follow：
● Six small & mid-sized biotech companies with high-growth potential in North America and China
●Topics including novel cellular therapies, epigenetics, diagnostics, modified release technologies, pharmaceutical R&D, etc
● H1 2022 North American Life Science Market Insights and Outlook reported by NAI 500 to participants
